SRPT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 2657 min ago

@ $134.67

Wydano: 6 geg. 2024 @ 19:46

Zwrot: 1.02%

Poprzedni sygnał: geg. 3 - 21:44

Poprzedni sygnał: Kupno

Zwrot: 1.13 %

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.96M
Średni wolumen	882 670
Kapitalizacja rynkowa	12.86B
EPS	$0 ( 2024-04-30 )
Następna data zysków	( $-0.0700 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	316.37
ATR14	$11.95 (8.77%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Murray Dallan	Sell	3 635	Common Stock
2024-04-24	Murray Dallan	Sell	0	Common Stock
2018-03-03	Murray Dallan	Sell	113	Stock Option (Right to buy)
2019-03-05	Murray Dallan	Sell	9 039	Stock Option (Right to buy)
2020-03-04	Murray Dallan	Sell	8 821	Stock Option (Right to buy)

INSIDER POWER
15.38
Last 99 transactions
Buy: 338 836 \| Sell: 333 998

Wolumen Korelacja

Długi: 0.73 (moderate)

Krótki: -0.74 (moderate negative)

Signal:(40) Neutral

Sarepta Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
TIG	0.913
CPLP	0.911
CCRC	0.9
ORTX	0.899
DSKE	0.888
XLNX	0.878
FXCO	0.878
VIA	0.876
HCCI	0.875
FGFPP	0.875

10 Najbardziej negatywne korelacje
GCBC	-0.914
WINT	-0.912
EJH	-0.91
AGIL	-0.909
XPDI	-0.899
BJDX	-0.898
UTRS	-0.891
CNSP	-0.89
LHDX	-0.887
PCSA	-0.887

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sarepta Therapeutics Inc Korelacja - Waluta/Towar

0.66
( moderate )

0.13
( neutral )

-0.56
( weak negative )

0.11
( neutral )

0.81
( strong )

0.75
( moderate )

Sarepta Therapeutics Inc Finanse

Annual	2023
Przychody:	$1.24B
Zysk brutto:	$1.09B (87.91 %)
EPS:	$-5.80

FY	2023
Przychody:	$1.24B
Zysk brutto:	$1.09B (87.91 %)
EPS:	$-5.80

FY	2022
Przychody:	$933.01M
Zysk brutto:	$793.02M (85.00 %)
EPS:	$-8.03

FY	2021
Przychody:	$701.89M
Zysk brutto:	$604.84M (86.17 %)
EPS:	$-5.15

Financial Reports:

No articles found.

Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.